Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover

Calcified Tissue International

Volumn 62, Issue 5, 1998, Pages 379-382

  Ongphiphadhanakul, B ^a   Piaseu, N ^a   Chailurkit, L ^a   Rajatanavin, R ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Bone turnover; Dosage study; Menopause; Osteoporosis; Salmon calcitonin

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM CARBONATE; CREATININE; DEOXYPYRIDINOLINE; SALCATONIN;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG CAPSULE; DRUG EFFECT; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND;

ADMINISTRATION, INTRANASAL; AMINO ACIDS; ANIMALS; BIOLOGICAL MARKERS; BONE RESORPTION; CALCITONIN; CALCIUM CARBONATE; CAPSULES; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; POSTMENOPAUSE; SALMON;

EID: 0031894837     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900448     Document Type: Article

References (24)

1. Rico H, Hernandez ER, Revilla M, Gomez-Castresana F (1992) Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16:131-138
2. Rico H, Revilla M, Hernandez BR, Villa LF, Alvarez de Buergo M (1995) Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 56:181-185
3. Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis GP, Mazzuoli G, Miravet L, Passeri M, Cano RP, Rapado A, Ribot C (1992) Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 305:1124-1128
4. Chambers TJ, Moore A (1983) The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 57:819-824
5. Abbiati G, Arrigoni M, Grignani S, Longoni A, Bartucci F, Castiglioni C (1994) Effect of salmon calcitonin on deoxypyridinoline (Dpr) urinary excretion in healthy volunteers. Calcif Tissue Int 55:346-348
6. Johnston CC, Hui SL, Witt RM, Appledorn R, Baker RS, Longcope C (1985) Early menopausal changes in bone mass and sex steroids. J Clin Endocrinol Metab 61:905-911
7. Richelson LS, Wahner HW, Melton JL, Riggs BL (1994) Relative contributions of aging and estrogen deficiency to post-menopausal bone loss. N Engl J Med 311:1273-1275
8. Nilas L. Christiansen C (1988) Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest 18:529-534
9. Thompson W (1995) Estrogen replacement therapy in practice: trends and issues. Am J Obstet Gynecol 173:990-993
10. Ravn P, Wasnich RD, Thompson DE, Daley MS, Yates AJ (1996) Alendronate in the prevention of osteoporosis: EPIC study two-year result. J Bone Miner Res 11:S133
11. Reginster JY, Denis D, Albert A, Devoisy R, Lecart MP, Fontaine MA, Lambelin P, Franchimont P (1987) one-year controlled randomization trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481- 1483
12. Reginster JY, Denis D, Devoisy R, Lecart MP, DeLogueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P (1994) Long-term (3 year) prevention of trabecular postmenopausal bone loss with low dose intermittent nasal salmon calcitonin. J Bone Miner Res 9:69-73
13. Overgaard K (1994) Effect of intranasal calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 55:82-86
14. Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P (1995) A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. Am J Med 98:452-458
15. Overgaard K. Hansen MA, Jensen SB (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305: 556-561
16. Garnero P, Sornay-Rendu E. Chapuy MC, Delmas PD (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337-349
17. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ (1995) Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 98:331-335
18. Riis B, Thomsen K, Christiansen C (1987) Does calcium supplementation prevent postmenopausal bone loss? N Engl J Med 316:173-177
19. Civitelli R, Gonelli S, Zaccei F, Rifazzi S, Vatimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268-1274
20. Harris ET, Hertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, Ricerca E, Chestnut CH (1993) The effect of short-term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399-1403
21. Stevenson JC, Cust MP, Gangar KF (1990) Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 336:265-267
22. Azria M (1995) Twenty-five years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 57:405-408
23. Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD (1995) Down regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167-171
24. Reginster JY, Caspar S, Deroisy R, Zegels B, Franchimont P (1993) Prevention of osteoporosis with nasal salmon calcitonin-effect of anti-salmon calcitonin antibody formation. Osteoporos Int 3:261-264